ESCALA DE DISCAPACIDAD DE KURTZKE PDF!
Treinta pacientes con EM con moderada discapacidad según la Escala Expandida de Kurtzke (EDSS) con puntuación entre a fueron. The Expanded Disability Status Scale (EDSS) and the Functional Systems Score (FSS) together describe severity of disability in patients with g: escala discapacidad. Escala de valor [predicho]/estado de/por discapacidad expandida . Expanded Disability Status Scale: escala de discapacidad Kurtzke.
|Published:||14 March 2017|
|PDF File Size:||35.41 Mb|
|ePub File Size:||17.65 Mb|
EDSSp | English to Spanish | Medical: Health Care
The treatment was repeated for 4 consecutive months. In the second clinical trial, the Cladribine dose used was 0. The treatment was repeated for 6 consecutive months. Furthermore, a phase III placebo-controlled study in patients with primary progressive multiple sclerosis PP or secondary progressive PS was performed Rice at al.
ES2382554T3 - cladribine dosage regimen for treating multiple sclerosis - Google Patents
Escala de discapacidad de kurtzke this study, both patient groups received Cladribine by subcutaneous injection at a dose of 0.
The treatment was repeated for 2 months or 6 months. USA, 93, ; Romine et al. Romine et al, above. Beutler et al,Acta hematol, 91, some adverse effects AEssuch as increased related compromised immune function or myelosuppression, with the highest doses Selby et al infections incidence,previously observed: Due to the narrow margin of safety between the effective dose and the dose of occurrence of AEs, to date, all clinical trials for Cladribine in multiple sclerosis have been conducted using iv administration or sc As a result, Beutler et al.
For some patients, a single retreat 5 days was performed at a cumulative dose of 0. It was said that the side effects seen with the previous regimen were less escala de discapacidad de kurtzke than those observed in the study in patients suffering from chronic progressive multiple sclerosis treated by iv infusion of Cladribine Sipe et al.
In addition, the therapeutic efficacy of the above oral dosage regimen versus infusion therapy iv questioned Grieb et al.
Expanded Disability Status Scale - Wikipedia
The invention is directed towards the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, wherein the escala de discapacidad de kurtzke is to be administered orally, as defined in the claims.
In particular, the invention is directed towards the use of Cladribine for the preparation of a medicament for the treatment of relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis and wherein are possible retreatment.
One embodiment described herein provides for improved cladribine in the treatment of multiple sclerosis, as defined in the claims regimen.
A further embodiment of the invention provides a use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis wherein adverse effects are reduced, allowing further use of Cladribine as defined in the claims.
In one embodiment, the invention provides a use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis wherein the formulation is to be administered orally following the sequential steps below: In another embodiment, the invention provides a pharmaceutical formulation of cladribine for use in treating multiple sclerosis, comprising the oral administration of Cladribine or of a formulation thereof to a patient in need thereof following the sequential steps continuation: The "total dose" or "cumulative dose" refers to the total dose of cladribine administered during treatment, i.
For example, the total dose corresponding to a treatment escala de discapacidad de kurtzke 0.
For example, the total effective dose corresponding to a treatment of 0. Typically, a treatment according to the invention comprises an "induction treatment" and about one or two or three maintenance treatments.
Rehabilitación integral de la enfermedad cerebrovascular
Typically, a treatment according to escala de discapacidad de kurtzke invention is of 2 years 24 months or 3 years 36 months or 4 years 48 months. An "induction treatment" involves the sequential succession of i an induction period wherein Cladribine or a pharmaceutical preparation of the invention cladribine orally administered and ii a cladribine-free period.
An induction period lasts up to 4 months or up to 3 escala de discapacidad de kurtzke or up to 2 months. Value of somatosensory and motor evoked potentials in precediting arm recovery after a stroke Record Supplied By Publisher. PET imaging of cerebral perfusion and oxygen consuption in acute ischemic stroke: Metabolic and clinic correlates of acute ischemic infaction.
Cerebral glucose metabolism as a predictor of rehabilitation after ischemic stroke.
Lichtenstein M et al. Cerebral hypoperfusion in stroke prognosis and brain recovery. Computed tomography findings in the first few hours of ischemic stroke: Post-stroke hemiplegia assessment of physical properties.